Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.

Abstract: The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a physical form that potentially inhibits (e.g. does not permit easy) access of iron sequestered by the compositions to the cells being targeted. Compositions comprising chelating aspects affixed to or incorporated into suitable carrier materials such that the resulting metal chelating composition is soluble in aqueous media are also provided. Disclosed herein are chelating compositions, for chelating one or more essential metals.

Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Abstract: The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.

Abstract: Mesoporous carriers for delivering targets into a cell are provided. The mesoporous carriers comprise hollow silica nanospheres (HSN) or mesoporous silica nanoparticles (MSN) and the targets bound to or encapsulated by the hollow silica nanospheres or the mesoporous silica nanoparticles. The targets includes at least two different targets, and the targets may include peptides, proteins, enzymes and/or enzymatic mimetics.

Abstract: Multistage nanostructures, e.g., for delivery of agents such as imaging agents and therapeutic agents to tumor vasculature.

Abstract: Provided are compositions and methods for transport, monitoring the transport, and controlled release of active agents. The compositions comprise surface functionalized iron oxide nanoparticles. The iron oxide nanoparticles are surface functionalized with cucurbitril[7] macrocycles. The cavity formed by the CB[7] macrocycles can be used for storage and transport of active agents. The active agents may be imaging agents or may be therapeutic agents which can be released by applying an alternating magnetic field at desired locations.

Abstract: Described herein are compositions in nanofibre form including one or more bioactive compounds releasably incorporated thereon. In one embodiment a composition is described comprising at least one nanofibre and at least one bioactive compound. The nanofibres are formed from a base material that is solubilised with the bioactive or bioactives in an aqueous based solvent solution and the base material and bioactives are together spun via electrospinning to form dry fibres with the bioactives chemically bonded to the nanofibres and the bioactives remaining stable during storage of the composition under ambient conditions substantially free of moisture. On exposure to moisture, the nanofibres dissolve, thereby releasing the bioactives.

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

Abstract: The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome.

Abstract: The present invention provides a device for administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as an oral dissolving film formed therefore.

Abstract: This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.

Abstract: The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.

Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.

Abstract: A magnetic resonance imaging enhancement agent includes a plurality of particles. Each particle including a metal core; a dielectric shell disposed on the metal core including water and at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.

Abstract: Fluoridated organofluoroborates comprising at least one 18F atom and precursors thereto, for use in PET scanning.

Abstract: A compound having a structure represented by the general formula (I): (wherein n is 0 or 1; R1 represents a hydrogen atom (only if n=0), a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, an optionally substituted amino group, an optionally substituted phenyl group, a C1-C6 alkylthio group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group or a C7-C12 aralkyloxy group; R2 represents —(CH2)p—[O(CH2)q]r—X (wherein X is a halogen atom, p is an integer of 1 to 6, q is an integer of 1 to 4, and r is an integer of 0 to 4); R3 represents a hydrogen atom, a C1-C6 alkyl group, a C7-C16 aralkyl group or a C6-C14 aryl group; and R4 represents a hydrogen atom or a C1-C6 alkyl group), or a pharmaceutically acceptable salt thereof excels FAMT in terms of the tendency to accumulate intensively in cancer, the affinity for LAT1 and the selectivity for cancer, and can be labeled using an automated synthesizer in clinical settings, and therefore is useful as a highly versatile PET imaging agent.

Abstract: An ultraviolet irradiation system includes a medical device having a central lumen, an optical fiber having a longitudinal length, and an ultraviolet wave generator, wherein ultraviolet waves generated by the wave generator are dispersed along the longitudinal length of the optical fiber to disinfect the central lumen of the medical device.

Abstract: Introducing ultraviolet (UV) light to activate a light sensitive chemical compound applied to interior portions of footwear alters the environment inside a shoe or other footwear to destroy microorganisms or inhibit their growth. Visible light can also be used to prevent further microorganism growth. Introducing forced air flow through the footwear removes dampness in and thereby deodorizes the footwear. A preferred embodiment comprises an adjustable shoe tree equipped with a UV germicidal light source and electronic safeguards that prevent appreciable leakage of UV radiation outside the shoe.

Abstract: The present invention relates to fragrance enhancers for use in conjunction with candles to enhance the dispersion of the fragrance therefrom and/or increase the combustion efficiency thereof. In one embodiment, the fragrance enhancer of the present invention comprises a body that is mounted to an upper surface of the holder and further comprises a mounting bracket for holding a fan assembly that is mounted to the holder. In one instance, the fan assembly includes a plurality of inverted blades, and a gap is formed between the body and the holder to enable air flow through the body. In another embodiment the fragrance enhancer of the present invention comprises a cylindrically-shaped perforated body, the cylindrically-shaped perforated body having openings located at both the top and bottom thereof. In this embodiment the fragrance enhancer of the present invention further comprises a fan assembly formed from inclined blades.

Abstract: An improvement to UV sterilization and disinfection devices and methods is disclosed. An apparatus for sterilization and disinfection includes: a compact, highly effective air sterilization and disinfection apparatus, which delivers clean, pure air directly into a blower/warmer device for clean and effective management of patient body temperature.

Abstract: A photo-catalyzing fluid mobilizing system and method are disclosed. A chamber has a power source. A fluid mobilizer is mounted in the chamber and connected with the power source to mobilize a fluid through the chamber. The fluid mobilizer includes one or more fan blades that are coated with a photo catalyst. A UV light source is mounted in the chamber proximate the fluid mobilizer and connected with the power source to catalyze the photo catalyst coating the blades to purifier the fluid being mobilized thereover.

Abstract: Systems, methods, and apparatuses for modulating proteases including matrix metalloproteinase (MMP), elastase, and bacterial protease in a negative pressure therapy system are described. A mesh having a sacrificial substrate is included. The sacrificial substrate includes a plurality of collagen fibers reinforced with a supporting material and intersecting with each other to form a network of collagen fibers having a plurality openings. The openings of the plurality of openings have an average area between about 0.5 mm2 and about 20 mm2 to permit the flow of negative pressure through the mesh. The sacrificial substrate can also include oxidized regenerated cellulose.

Abstract: A method of causing delayed hemostasis. A hemostatic product is formed by applying a hemostatic agent to a dextran support. The hemostatic agent is provided with at least one of a reduced concentration and a reduce availability. The hemostatic product is applied to a wound from which blood is being discharged. At least one foreign object or pathogen is proximate the wound. Hemostasis is progressively caused so that blood continues to be discharged from the wound to cause the at least one foreign object or pathogen to move away from the wound.

Abstract: A wetness indicating composition is provided, comprising a liquid-activated colorant, a permanent colorant, and a binding matrix.

Abstract: Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

Abstract: A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water.

Abstract: The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component.

Abstract: The present invention provides, among other things, a composite device comprised of a porous polymer membrane carrying active growth factors. Composite devices are characterized by an ability to controllably degrade for repair of bone and/or tissue defects sustained from traumatic wounds or congenital defects through eluting growth factor over readily adapted time scales inducing a natural wound healing cascade and rapid bone repair. Methods of making and using provided devices are also disclosed.

Abstract: Additive manufacturing powder contains a core-shell type particle containing a core particle comprising a first binder resin and a filler and a shell present on the surface of the core particle. The shell contains a second binder resin. The powder has a particle size distribution Dv/Dn of 1.5 or less and an average circularity of from 0.800 to 0.980, the average circularity being represented by the following relation: Average circularity=(a perimeter of a circle having the same area as a projected image of a particle)/(the perimeter of the projected image of the particle)×100.

Abstract: Uses of compositions comprising carboxypolysaccharides (CPS) including carboxymethyl cellulose (CMC) and polyethylene glycols (PEGs) are provided where the PEG is a PEG-epoxide covalently linked to the CPS in the presence of NH4OH. In certain embodiments, the PEG attaches to only one CPS, forming a decorated CPS. In other embodiments, bi-functional PEG molecules are attached to adjacent CPSs, thereby forming a covalently cross-linked composition. Such compositions can be used as space-filling materials, load-bearing materials, anti-adhesion compositions, drug delivery vehicles, and lubricants of tissues and medical instruments.

Abstract: The present invention refers to a composition that is useful as a filler for the correction of soft tissue volume loss, for example for the cosmetic treatment of wrinkles, or for the treatment of disorders such as lipoatrophy or lipodystrophy in general, said composition comprising agarose and hyaluronic acid, or a pharmaceutically acceptable salt thereof. The particular interaction that takes place between the two components makes even high concentrations of agarose injectable and tolerable, said high concentrations being particularly useful for ensuring the duration and stability over time of the aesthetic results that are achievable using this filler.

Abstract: The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices.

Abstract: The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be shaped into 3-dimentional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Abstract: A bone repair composition including a cancellous bone matrix with cortical and/or cancellous bone particles loaded therein; and a kit comprising the cancellous bone matrix and the cortical and/or cancellous bone particles.

Abstract: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.

Abstract: Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

Abstract: Compositions and methods for augmenting bone formation by administering isolated human mesenchymal stem cells (hMSCs) within a matrix provided. By adding calcium and/or phosphate ions to the matrix, one may foster greater bone regeneration.

Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: The present application describes a polymeric mesh for the repair and regeneration of tissues from an organism that comprises pores wherein at least 70% of the pores of the said mesh have a size smaller than the one required to confine the cells of the said tissues, and wherein at least 70% of the pores of the said mesh has a size superior than the one needed for the passage of interstitial fluids of the said tissues; the degradation time of the said polymeric mesh within the organism is at least 8 weeks; the said polymeric mesh has an apparent tensile strength superior than 1 MPa; the said polymeric mesh has an apparent elastic modulus superior than 0.1 MPa. The mesh described in this application allows that the “new tissue” formed presents very similar properties to the ones of the damaged tissue.

Abstract: The invention features biodegradable materials, and in vitro and in vivo methods of using such compositions to promote bone and soft tissue growth and healing.

Abstract: A fluoropolymer medical device (e.g., a sphincterotome) has a thin-film coating deposited using a technique such as Atomic Layer Deposition. The thin-film coating may be a ceramic coating or a metal coating and a ceramic coating may further have an overlying ink coating such as a conducting ink or a radiopaque marker. The ceramic coating improves the application and adherence of the ink coating to the fluoropolymer device.

Abstract: Various aspects of the present disclosure provide compositions, coatings and implantable devices including a drug and an excipient. In certain embodiments the excipient and the drug are present at a weight ratio of between 10 to 1 and 1 to 10 drug to excipient. In certain other embodiments, the excipient and the drug form particles in which the drug is encapsulated by the excipient. Other aspects of the disclosure provide methods of manufacturing and using such compositions, coatings and implantable devices.

Abstract: The present invention provides a stretchable material suitable for use in an inflatable medical device. The stretchable material has at least one reinforcing polymer layer with a top and bottom side forming a porous matrix which is imbibed with a sealing material to infiltrate and substantially seal spaces of the porous matrix and extend beyond the reinforcing polymer layer to form a surface coating.

Abstract: A cystostomy device for implant in a patient includes a transcutaneous sleeve a flange connected to the transcutaneous sleeve, adapted to reduce contamination of an outer surface of said transcutaneous sleeve, a catheter defining a passage for the flow of fluids from within the patient to outside the patient, an inner surface of the transcutaneous sleeve defining a path through which the catheter passes, and an anchor adapted for implantation into the biological tissue of the patient, the anchor connecting to the catheter and the transcutaneous sleeve. At least one microbe resistance zone is included on surfaces in any of the sleeve, the flange, and the catheter. The microbe resistance zone may be formed on the surfaces of the sleeve, flange and catheter, or may be adhered to the device as tape that may be rolled. A micropore filter prevents back flow of urine from a urinary bag.

Abstract: The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent.

Abstract: This invention relates to methods of applying to a substrate a hydrophilic coating that becomes lubricious when activated with water or water vapor, and to substrates having such a hydrophilic coating.